{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:34:03Z","timestamp":1787027643676,"version":"build-2736575974"},"reference-count":25,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T00:00:00Z","timestamp":1730332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Chiesi Poland Sp. z o.o. grant","award":["PR 10748316"],"award-info":[{"award-number":["PR 10748316"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ARM"],"abstract":"<jats:p>Medication non-adherence remains a substantial obstacle in asthma care, prompting the exploration of novel therapeutic modalities that prioritize rapid symptom relief, anti-inflammatory activity, and facilitate patients\u2019 compliance. This task is well-served by the following new form of therapy: inhaled triple-combination medications ICS\/LABA\/LAMA (inhaled glucocorticosteroid\/long-acting beta2-agonist\/long-acting muscarinic antagonist). The integration of three medications within a singular inhalation device culminates in the reduction of the effective dose of the principal therapeutic agent for asthma management, namely ICS. This consolidation yields a dual benefit of minimizing the likelihood of adverse effects typically linked with ICS while concurrently optimizing bronchodilator efficacy. The accumulated evidence suggests that adding LAMA to a medium- or high-dose ICS\/LABA results in a decrease of asthma exacerbations compared to medium- or high-dose ICS\/LABA alone, accompanied by sustained enhancements in lung function parameters. In adult patients experiencing suboptimal asthma control despite medium\/high-dose ICS\/LABA treatment\u2014regardless of adherence to GINA-recommended strategies, such as MART therapy as a first-line approach, or alternative second-line strategies\u2014we propose that the preferred course for intensifying asthma therapy involves the addition of a LAMA, ideally in the form of SITT.<\/jats:p>","DOI":"10.3390\/arm92060041","type":"journal-article","created":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T10:42:40Z","timestamp":1730803360000},"page":"452-465","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["2024 Update on Position Statement by Experts from the Polish Society of Allergology and the Polish Respiratory Society on the Evaluation of Efficacy and Effectiveness of Single Inhaler Triple Therapies in Asthma Treatment"],"prefix":"10.3390","volume":"92","author":[{"given":"Pawe\u0142","family":"\u015aliwi\u0144ski","sequence":"first","affiliation":[{"name":"2nd Department of Respiratory Medicine, Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Antczak","sequence":"additional","affiliation":[{"name":"Department of General and Oncological Pulmonology, Medical University of Lodz, 90-419 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6567-9208","authenticated-orcid":false,"given":"Adam","family":"Barczyk","sequence":"additional","affiliation":[{"name":"Department of Pneumology, Faculty of Medical Sciences, Medical University of Silesia, 40-635 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3501-167X","authenticated-orcid":false,"given":"Adam J.","family":"Bia\u0142as","sequence":"additional","affiliation":[{"name":"Department of Pneumonology, Medical University of Lodz, 90-419 Lodz, Poland"},{"name":"Department of Pulmonary Rehabilitation, Regional Medical Center for Lung Diseases and Rehabilitation, Blessed Rafal Chylinski Memorial Hospital for Lung Diseases, 91-520 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5661-3816","authenticated-orcid":false,"given":"Ma\u0142gorzata","family":"Czajkowska-Malinowska","sequence":"additional","affiliation":[{"name":"Department of Lung Diseases and Respiratory Failure, Kuyavian-Pomeranian Pulmonology Center, 85-326 Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Jahnz-R\u00f3\u017cyk","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Pneumonology, Allergology and Clinical Immunology, Military Medical Institute\u2013National Research Institute, 04-141 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Kulus","sequence":"additional","affiliation":[{"name":"Department of Pediatric Pneumonology and Allergology, Warsaw Medical University, 02-091 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Kuna","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Asthma and Allergy, Medical University of Lodz, 90-153 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Kupczyk","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Asthma and Allergy, Medical University of Lodz, 90-153 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,31]]},"reference":[{"key":"ref_1","unstructured":"National Health Fund (2024, July 17). Healthy Data. Report, Available online: https:\/\/ezdrowie.gov.pl\/portal\/home\/badania-i-dane\/zdrowe-dane\/raporty\/nfz-o-zdrowiu-astma."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0149-2918(01)80109-0","article-title":"A systematic review of the associations between dose regimens and medication compliance","volume":"23","author":"Claxton","year":"2001","journal-title":"Clin. Ther."},{"key":"ref_3","first-page":"329","article-title":"Non adherence in difficult asthma\u2014Facts, myths, and a time to act","volume":"7","author":"Lindsay","year":"2013","journal-title":"Patient Prefer. Adherence"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2165\/00115677-200614040-00005","article-title":"Poor adherence to anti-inflammatory medication in asthma","volume":"14","author":"Elliott","year":"2006","journal-title":"Dis. Manag. Health Out."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Azzi, E., Srour, P., Armour, C., Rand, C., and Bosnic-Anticevich, S. (2017). Practice makes perfect: Self-reported adherence a positive marker of inhaler technique maintenance. NPJ Prim. Care. Respir. Med., 27.","DOI":"10.1038\/s41533-017-0031-0"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"42","DOI":"10.5603\/ARM.57885","article-title":"Triple-drug therapy for chronic obstructive pulmonary disease from a single inhaler versus adherence to therapy","volume":"86","author":"Kuziemski","year":"2018","journal-title":"Adv. Respir. Med."},{"key":"ref_7","unstructured":"(2024, July 17). GINA 2023 Report. Available online: https:\/\/ginasthma.org\/2023-gina-main-report\/."},{"key":"ref_8","unstructured":"\u015aliwi\u0144ski, P. (2024, July 17). New Treatment Strategy for Asthma Patients. Available online: https:\/\/www.medexpress.pl\/leki-technologie-medyczne\/nowa-strategia-leczenia-dla-pacjentow-z-astma-79933\/."},{"key":"ref_9","first-page":"186","article-title":"Expert position of the Polish Society of Allergology and the Polish Respiratory Society on new combination inhaled IND\/MF and IND\/GB\/MF drugs for the treatment of asthma","volume":"1","author":"Antczak","year":"2020","journal-title":"Pneum. Pol."},{"key":"ref_10","first-page":"120","article-title":"Expert position of the Polish Society of Allergology and the Polish Respiratory Society on new combination inhaled drugs for the treatment of asthma","volume":"2","author":"Antczak","year":"2021","journal-title":"Pneum. Pol."},{"key":"ref_11","unstructured":"European Medicines Agency, TRIMBOW (2024, July 17). Summary of Product Chartacteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/trimbow-epar-product-information_en.pdf."},{"key":"ref_12","unstructured":"European Medicines Agency, ENERZAIR (2024, July 17). Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/enerzair-breezhaler-epar-product-information_en.pdf."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Kuna, P., Jerzynska, J., Martini, M., Vele, A., Barneschi, I., Mariotti, F., Georges, G., and Ciurlia, G. (2022). Pharmacokinetics of extrafine beclomethasone dipropionate\/formoterol fumarate\/glycopyrronium bromide in adolescent and adult patients with asthma. Pharmacol. Res. Perspect., 10.","DOI":"10.1002\/prp2.980"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Papi, A., Singh, D., Virchow, J.C., Canonica, G.W., Vele, A., and Georges, G. (2022). Normalization of airflow limitation in asthma: Post-hoc analyses of TRIMARAN and TRIGGER. Clin. Transl. Allergy., 12.","DOI":"10.1002\/clt2.12145"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S2213-2600(22)00185-0","article-title":"Predictors and associations of the persistent airflow limitation phenotype in asthma: A post-hoc analysis of the ATLANTIS study","volume":"11","author":"Kole","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Singh, D., Virchow, J.C., Canonica, G.W., Vele, A., Kots, M., Georges, G., and Papi, A. (2020). Determinants of response to inhaled extrafine triple therapy in asthma: Analyses of TRIMARAN and TRIGGER. Respir. Res., 21.","DOI":"10.1186\/s12931-020-01558-y"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Gessner, C., Akyildiz, B., Pohl, W., Nachtigall, D., Russell, R., Bogoevska, V., Ulrik, C.S., and Watz, H. (2023). Impact of extrafine formulation Single-inhaler Triple Therapy on asthma control and health-related quality of life after three months of treatment in patients with asthma: Trimaximize\u2014A real-world view from Germany, United Kingdom, Austria and Denmark. Am. J. Respir. Crit. Care Med., 207.","DOI":"10.1164\/ajrccm-conference.2023.207.1_MeetingAbstracts.A6649"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Dragonieri, S., Quaranta, V.N., Portacci, A., and Carpagnano, G.E. (2023). Can single-inhaler beclomethasone dipropionate\/formoterol fumarate\/glycopyrronium therapy postpone or save biologics for severe asthma?. Pulm. Pharmacol. Ther., 83.","DOI":"10.1016\/j.pupt.2023.102270"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Orlovic, M., Magni, T., Lukyanov, V., Guerra, I., and Madoni, A. (2022). Cost-effectiveness of single-inhaler extrafine beclomethasone dipropionate\/formoterol fumarate\/glycopyrronium in patients with uncontrolled asthma in England. Respir. Med., 201.","DOI":"10.1016\/j.rmed.2022.106934"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2147\/JAA.S283489","article-title":"Potential drawbacks of ICS\/LABA\/LAMA triple fixed-dose combination therapy in the treatment of asthma: A quantitative synthesis of safety profile","volume":"15","author":"Rogliani","year":"2022","journal-title":"J. Asthma. Allergy"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s40261-021-01067-w","article-title":"Cost-utility analysis of fixed-dose combination of indacaterol acetate, glycopyrronium bromide and mometasone furoate as a maintenance treatment in adult patients with asthma not adequately controlled with a maintenance combination of a long-acting beta2-agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year","volume":"41","author":"Mangia","year":"2021","journal-title":"Clin. Drug. Investig."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Scosyrev, E., van Zyl-Smit, R., Kerstjens, H., Gessner, C., Kornmann, O., Jain, D., Aubrun, E., D\u2019Andrea, P., Hosoe, M., and Pethe, A. (2021). Cardiovascular safety of mometasone\/indacaterol and mometasone\/indacaterol\/glycopyrronium once-daily fixed-dose combinations in asthma: Pooled analysis of phase 3 trials. Respir. Med., 180.","DOI":"10.1016\/j.rmed.2021.106311"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s41030-023-00225-z","article-title":"Medication adherence and asthma control with once-daily indacaterol\/glycopyrronium\/mometasone furoate Breezhaler Digital Companion: 90-day analysis from Germany","volume":"9","author":"Woehrle","year":"2023","journal-title":"Pulm. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s41030-023-00234-y","article-title":"Triple therapy with mometasone\/indacaterol\/glycopyrronium or doubling the ICS\/LABA dose in GINA Step 4: IRIDIUM Analyses","volume":"9","author":"Kerstjens","year":"2023","journal-title":"Pulm. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Van Zyl-Smit, R.N., Kerstjens, H.A., Maspero, J.F., Kostikas, K., Hosoe, M., Tanase, A.M., D\u2019Andrea, P., Mezzi, K., Brittain, D., and Lawrence, D. (2023). Efficacy of once-daily, single-inhaler, fixed-dose combination of mometasone\/indacaterol\/glycopyrronium in patients with asthma with or without persistent airflow limitation: Post-hoc analysis from the IRIDIUM study. Respir. Med., 211.","DOI":"10.1016\/j.rmed.2023.107172"}],"container-title":["Advances in Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2543-6031\/92\/6\/41\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:25:50Z","timestamp":1760113550000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2543-6031\/92\/6\/41"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,31]]},"references-count":25,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["arm92060041"],"URL":"https:\/\/doi.org\/10.3390\/arm92060041","relation":{},"ISSN":["2543-6031"],"issn-type":[{"value":"2543-6031","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,31]]}}}